Widgetized Section

Go to Admin » Appearance » Widgets » and move Gabfire Widget: Social into that MastheadOverlay zone

Report: Merck’s Uprifosbuvir Faces Fight to Be Profitable

Published Tuesday March 14


Photo: Pharmpro

Merck’s uprifosbuvir faces fight to be profitable in declining hepatitis C market, says GlobalData.

Due to various setbacks and adverse market dynamics, Merck & Co.’s newest direct-acting antiviral for hepatitis C, uprifosbuvir, will represent only a minor player in the hepatitis C market by 2025, according to research and consulting firm GlobalData.

Article length: About 290 words.
Tags: Patent Acquired Purchase
Read more at Pharmpro